SmithKline Beecham has launched a new single-dose formulation of its hepatitis A vaccine Havrix in the UK. Havrix Junior Monodose is the first single-dose pediatric vaccine to be made available in the UK, notes the company. A single-dose adult version has been available for some time.
SB's first pediatric hepatitis A vaccine, Havrix Junior, requires a primary two-dose course and a booster. Children immunized with a single dose of Havrix Junior Monodose will be protected for at least one year, but will need a booster at between six and 12 months to achieve persistent immunity of up to 10 years.
The company notes that the single-dose format will help clinics achieve their vaccination targets more easily.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze